Valeant CEO Staunchly Defends Drugmaker's Accounting, Ethics – Bloomberg

Valeant CEO Staunchly Defends Drugmaker’s Accounting, Ethics – Bloomberg


Financial Times

Valeant CEO Staunchly Defends Drugmaker’s Accounting, Ethics
Bloomberg
Valeant Pharmaceuticals International Inc. Chief Executive Officer J. Michael Pearson struck back at critics of the company’s accounting and financial disclosures, saying the drugmaker had behaved properly in its relationship with a mail-order pharmacy.
Valeant Forms Board Committee to Review Philidor ArrangementWall Street Journal
Valeant Pharma (VRX) Says Philidor Accounting is AppropriateStreetInsider.com
Valeant to Review Philidor AccountingNasdaq
Financial Times –Seeking Alpha
all 278 news articles »

Valeant CEO Staunchly Defends Drugmaker’s Accounting, Ethics – Bloomberg